Immatics (NASDAQ:IMTX) Sees Large Growth in Short Interest

Immatics (NASDAQ:IMTX) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 8,910,000 shares, a growth of 6.2% from the March 15th total of 8,390,000 shares. Based on an average trading volume of 526,500 shares, the short-interest ratio is currently 16.9 days.

Institutional Investors Weigh In On Immatics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. purchased a new stake in Immatics in the 3rd quarter valued at about $3,781,000. TD Asset Management Inc boosted its position in shares of Immatics by 102.8% in the third quarter. TD Asset Management Inc now owns 197,718 shares of the company’s stock worth $2,290,000 after buying an additional 100,200 shares during the period. Walleye Capital LLC acquired a new position in Immatics during the 3rd quarter worth $1,318,000. Hudson Bay Capital Management LP grew its position in shares of Immatics by 8.1% during the 3rd quarter. Hudson Bay Capital Management LP now owns 400,580 shares of the company’s stock valued at $4,639,000 after buying an additional 30,000 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Immatics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock worth $121,000 after acquiring an additional 2,916 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Trading Down 0.2 %

NASDAQ:IMTX opened at $10.38 on Wednesday. Immatics has a 1-year low of $6.31 and a 1-year high of $13.16. The firm’s fifty day moving average price is $11.52 and its 200 day moving average price is $10.45.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Immatics had a negative return on equity of 43.58% and a negative net margin of 179.67%. The firm had revenue of $17.14 million for the quarter, compared to analyst estimates of $11.78 million. Research analysts expect that Immatics will post -1.44 EPS for the current year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.